Secretin Enhanced MRCP for Evaluation of the Known or Suspected Intraductal Papillary Mucinous Neoplasms of the Pancreas
Information source: Massachusetts General Hospital
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Intraductal Papillary Mucinous Neoplasms
Intervention: RG1068 (Synthetic Human Secretin) (Drug)
Phase: Phase 1
Status: Terminated
Sponsored by: Massachusetts General Hospital Official(s) and/or principal investigator(s): Dushyant V Sahani, Principal Investigator, Affiliation: Massachusetts General Hospital
Summary
1. To assess the effect of RG1068 at a dose of 0. 2 mcg/kg intravenously (IV) on the
diameter of the pancreatic duct when used during Magnetic Resonance Pancreatography
2. To demonstrate that RG1068-enhanced MRCP improves detection and characterization of
intraductal papillary mucinous neoplasms (IPMN) relative to unenhanced MRCP in patients
with suspected IPMN
3. To correlate findings on MRCP with histologically confirmed malignancy
Clinical Details
Official title: RG1068 (Synthetic Human Secretin) Enhanced MRCP for Morphological Evaluation of the Known or Suspected Intraductal Papillary Mucinous Neoplasms of the Pancreas
Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Primary outcome: MR & MRCP - Images will be evaluated for quality, main and branch duct visualization, ductal diameter and improved visualization of structural abnormalities with and without use of RG1068.
Secondary outcome: Laboratory
Detailed description:
Until relatively recently, endoscopic retrograde cholangiopancreatography (ERCP) was the
primary diagnostic and therapeutic modality for assessing patients with suspected pancreatic
disease or abnormalities. However, this invasive procedure carries with it a significant
potential for complications including acute pancreatitis, hemorrhage and infection, as well
as reactions to contrast material or premedications and exposure to radiation. In addition,
the success of such procedures, both from the standpoint of safety and efficacy, is highly
dependent on the skill of the endoscopist, and the cost of ERCP is relatively high.
The advent of magnetic resonance imaging has resulted in the development of a less
expensive, non-invasive, radiation-free means of assessing the pancreaticobiliary system:
Magnetic Resonance Cholangiopancreatography (MRCP). MRCP uses stationary water in biliary
and pancreatic secretions as an intrinsic contrast medium, thus facilitating examination of
pancreatic and biliary ducts and surrounding tissue. Secretin, which promotes the secretion
of pancreatic fluid into the pancreatic ducts, can thereby enhance the MR imaging signal,
improving delineation of both normal and abnormal structures, as well as highlighting
abnormal fluid collections and leakage. Conversely, filling defects can indicate the
presence of stones or mass lesions.
This study is being undertaken to prospectively assess the effectiveness of RG1068-enhanced
MRCP relative to unenhanced MRCP for the evaluation of patients with known or suspected
IPMN. RG1068 is a synthetic human secretin with a pharmacological profile very similar to
that of biological and synthetic porcine secretins. Secretin is a 27-amino acid
gastrointestinal peptide hormone that is produced by S-cells in the duodenum in response to
the pH decrease caused by the passage of partially digested food from the stomach into the
intestine. RG1068 is identical in amino acid sequence to naturally occurring human secretin
and differs from porcine secretin in 2 amino acids.
Eligibility
Minimum age: 18 Years.
Maximum age: 90 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Males and females older than 18 years of age
- Is clinically indicated for MRCP of the pancreas based on prior imaging features
suggestive or suspicious of IPMN (eg. Cystic lesion in the pancreas along the duct,
ductal dilatation)
- Scheduled for MRCP and therapeutic or diagnostic ERCP or surgery for the IPMN
- Has been fully informed and has personally signed and dated the Written Informed
Consent and Health Insurance Portability Accountability Act (HIPAA) provisions
- Is a male, or is a female not of childbearing potential, or is a female of
childbearing potential who is using effective contraception and has a negative serum
pregnancy test on the same day, but prior to, study drug administration
- Is able and willing to complete all study procedures specified in the protocol
Exclusion Criteria:
- Presence of a pancreatic stent
- History of any clinically significant cardiac, endocrinologic, hematologic, hepatic,
immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric,
renal, and/or other major disease which, in the opinion of the investigator,
precludes study participation
- History of sensitivity to any of the ingredients in the study drug
- Pregnancy
- Any contraindication to MRI procedure, including but not limited to implanted metal
devices (e. g., pacemaker, aneurysm clips, cochlear implants)
Locations and Contacts
Massachusetts General Hospital, Boston, Massachusetts 02114, United States
Additional Information
Starting date: February 2008
Last updated: January 27, 2009
|